{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:35:39Z","timestamp":1762079739209},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Therapie der ersten Wahl gem\u00e4\u00df Leitlinie ist bei gew\u00f6hnlicher Skabies in Deutschland die topische Einmalbehandlung mit Permethrin 5\u202f% Creme. In den letzten Jahren gab es im Zuge zunehmender Skabiesinzidenz vermehrt Meldungen \u00fcber ein Nachlassen der Wirksamkeit der Standardtherapie.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel<\/jats:title>\n                <jats:p>Um ein besseres Verst\u00e4ndnis von der Wirksamkeit der Skabiestherapie unter Praxisbedingungen zu entwickeln, wurde eine Umfrage mit besonderem Fokus auf die Erstlinientherapie mit Permethrin in dermatologischen Kliniken, Ambulanzen und Hautarztpraxen durchgef\u00fchrt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>In der postalischen Umfrage unter allen in Deutschland dermatologisch t\u00e4tigen \u00c4rzten wurden die bevorzugten Diagnoseverfahren, die jeweilige Standardinitialbehandlung, die wahrgenommene Wirksamkeit der Permethrin-Therapie, die H\u00e4ufigkeit und die Gr\u00fcnde f\u00fcr ein m\u00f6gliches Therapieversagen unter Permethrin und das therapeutische Vorgehen bei Versagen der Initialtherapie erfragt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die Wirksamkeit von Permethrin wurde von 187\u00a0\u00c4rzten im Mittel mit 73\u202f% bewertet. Rund 74\u202f% behandeln weiterhin initial topisch mit 5\u202f%iger Permethrin-Creme. Die am h\u00e4ufigsten genannten Gr\u00fcnde f\u00fcr ein Therapieversagen waren Anwendungsfehler, mangelnde Compliance und unzureichende Hygienema\u00dfnahmen. Daneben wurde der Verdacht auf nachlassende Wirksamkeit, Resistenzentwicklung und Re-Infestationen ge\u00e4u\u00dfert. Bei Unwirksamkeit der Initialtherapie entscheiden sich die meisten \u00c4rzte f\u00fcr orales Ivermectin, eine Wiederholung der Permethrin-Therapie oder f\u00fcr eine Kombination aus beidem.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fazit<\/jats:title>\n                <jats:p>Obwohl lokal begrenzt \u00fcber ein Nachlassen der Wirksamkeit von Permethrin bei Skabies berichtet wird, deuten die Ergebnisse dieser Umfrage weiterhin auf eine gute Wirksamkeit der Erstlinientherapie mit Permethrin 5\u202f% Creme in Deutschland hin.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-020-04561-y","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T13:02:52Z","timestamp":1583499772000},"page":"374-379","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Skabiestherapie in Deutschland"],"prefix":"10.1007","volume":"71","author":[{"given":"B.","family":"Hackenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Petachti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Schult","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Yenig\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bannenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"issue":"11","key":"4561_CR1","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/ddg.13130_g","volume":"14","author":"C Sunderk\u00f6tter","year":"2016","unstructured":"Sunderk\u00f6tter\u00a0C, Feldmeier\u00a0H, F\u00f6lster-Holst\u00a0R et al (2016) S1-Leitlinie zur Diagnostik und Therapie der Skabies. AWMF online 2016, Reg.-Nr.\u00a0013-052. J\u00a0Dtsch Dermatol Ges 14(11):1160\u20131171","journal-title":"J Dtsch Dermatol Ges."},{"key":"4561_CR2","unstructured":"Insight Health Galaxy, NPI-Daten \u2013 Verkaufte Antiscabiosa in Deutschland 2012\u20132018, Abfrage 07\/2019"},{"issue":"15","key":"4561_CR3","first-page":"A-700\/B-604\/C-6","volume":"115","author":"E K\u00e4mmerer","year":"2018","unstructured":"K\u00e4mmerer E (2018) Skabies: Erfahrungen aus der Praxis. Dtsch Arztebl 115(15):A-700\/B-604\/C-605","journal-title":"Dtsch Arztebl"},{"issue":"45","key":"4561_CR4","first-page":"757","volume":"113","author":"C Dressler","year":"2016","unstructured":"Dressler\u00a0C, Rosumeck\u00a0S, Sunderk\u00f6tter\u00a0C et\u00a0al (2016) The treatment of scabies. Dtsch Arztebl Int 113(45):757\u2013762","journal-title":"Dtsch Arztebl Int"},{"key":"4561_CR5","unstructured":"IQVIA OneKey Health Care Professionals Datenbank, Fachgruppe Dermatologie, Stand 09\/2019: 7.651 dermatologisch t\u00e4tige \u00c4rzte."},{"issue":"5","key":"4561_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1610-0387.2006.05941.x","volume":"4","author":"H Hamm","year":"2006","unstructured":"Hamm\u00a0H, Beiteke\u00a0U, H\u00f6ger\u00a0PH et\u00a0al (2006) Treatment of scabies with 5\u202f% permethrin cream: results of a\u00a0German multicenter study. J\u00a0Dtsch Dermatol Ges 4(5):407\u2013413","journal-title":"J Dtsch Dermatol Ges"},{"key":"4561_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012994.","author":"S Rosumeck","year":"2018","unstructured":"Rosumeck\u00a0S, Nast\u00a0A, Dressler\u00a0C (2018) Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD012994","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4561_CR8","first-page":"15","volume":"17","author":"C Sunderk\u00f6tter","year":"2019","unstructured":"Sunderk\u00f6tter\u00a0C, Aebischer\u00a0A, Neufeld\u00a0M et\u00a0al (2019) Zunahme von Skabies in Deutschland und Entwicklung resistenter Kr\u00e4tzemilben? Evidenz und Konsequenz. J\u00a0Dtsch Dermatol Ges 17(1):15\u201324","journal-title":"J Dtsch Dermatol Ges."},{"issue":"1","key":"4561_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1365-2915.2008.00716.x","volume":"22","author":"C Pasay","year":"2008","unstructured":"Pasay\u00a0C, Walton\u00a0S, Fischer\u00a0K et\u00a0al (2008) High resolution melt analysis for the detection of a\u00a0mutation associated with permethrin resistance in a\u00a0population of scabies mites. Med Vet Entomol 22(1):82\u201388","journal-title":"Med Vet Entomol"},{"key":"4561_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1756-3305-3-43","volume":"3","author":"KE Mounsey","year":"2010","unstructured":"Mounsey\u00a0KE, Pasay\u00a0CJ, Arlian\u00a0LG et al (2010) Increased transciption of glutathione S\u2011transferases in acaricide exposed scabies mites. Parasit Vectors 3:43","journal-title":"Parasit Vectors"},{"issue":"1","key":"4561_CR11","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1371\/journal.pntd.0000354","volume":"3","author":"C Pasay","year":"2009","unstructured":"Pasay\u00a0C, Arlian\u00a0L, Morgan\u00a0M et\u00a0al (2009) The effect of insecticide synergists on the response of scabies mites to pyrethroid acaricides. PLoS Negl Trop Dis 3(1):e354","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"4561_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S0035-9203(00)90454-1","volume":"94","author":"SF Walton","year":"2000","unstructured":"Walton\u00a0SF, Myerscough\u00a0MR, Currie\u00a0BJ (2000) Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var hominis. Trans R Soc Trop Med Hyg 94(1):92\u201396","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"4561_CR13","doi-asserted-by":"publisher","first-page":"O139","DOI":"10.1111\/1469-0691.12334","volume":"20","author":"V Andriantsoanirina","year":"2014","unstructured":"Andriantsoanirina\u00a0V, Izri\u00a0A, Botterel\u00a0F et\u00a0al (2014) Molecular survey of knockdown resistance to pyrethroids in human scabies mites. Clin Microbiol Infect 20(2):O139\u2013O141","journal-title":"Clin Microbiol Infect"},{"key":"4561_CR14","unstructured":"\u00d6sterreichische Gesellschaft f\u00fcr Dermatologie und Venerologie (\u00d6GDV), \u00d6sterreichische Gesellschaft f\u00fcr STD und dermatologische Mikrobiologie (\u00d6GSTD) (2019) Skabies Therapiemanagement f\u00fcr Allgemeinmediziner und Fach\u00e4rzte. http:\/\/oegstd.at\/uploads\/Skabies_therapie_11-2019.pdf. Zugegriffen: 26.02.2020"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-020-04561-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:46:35Z","timestamp":1614991595000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-020-04561-y"}},"subtitle":["Ergebnisse einer bundesweiten Umfrage mit besonderem Fokus auf die Wirksamkeit der Erstlinientherapie mit Permethrin"],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4561"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04561-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"6 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Bannenberg ist Mitarbeiter der Firma InfectoPharm Arzneimittel und Consilium GmbH, Heppenheim. B.\u00a0Hackenberg, O.N.\u00a0Horv\u00e1th, M.\u00a0Petachti, R.\u00a0Schult und N.\u00a0Yenig\u00fcn geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}